ASND
Price:
$119.15
Market Cap:
$6.16B
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.[Read more]
Industry
Biotechnology
IPO Date
2015-01-28
Stock Exchange
NASDAQ
Ticker
ASND
According to Ascendis Pharma A/S’s latest financial reports and current stock price. The company's current PE Ratio is -12.52. This represents a change of -13.46% compared to the average of -14.47 of the last 4 quarters.
The mean historical PE Ratio of Ascendis Pharma A/S over the last ten years is -15.73. The current -12.52 PE Ratio has changed 7.86% with respect to the historical average. Over the past ten years (40 quarters), ASND's PE Ratio was at its highest in in the March 2015 quarter at 60.71. The PE Ratio was at its lowest in in the September 2019 quarter at -41.86.
Average
-15.73
Median
-14.90
Minimum
-27.28
Maximum
-7.45
Discovering the peaks and valleys of Ascendis Pharma A/S PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 91.74%
Maximum Annual PE Ratio = -7.45
Minimum Annual Increase = -175.26%
Minimum Annual PE Ratio = -27.28
Year | PE Ratio | Change |
---|---|---|
2023 | -13.32 | 21.48% |
2022 | -10.97 | -35.09% |
2021 | -16.89 | 2.47% |
2020 | -16.49 | -37.70% |
2019 | -26.46 | 53.38% |
2018 | -17.25 | 91.74% |
2017 | -9.00 | 20.73% |
2016 | -7.45 | -38.59% |
2015 | -12.14 | -55.52% |
2014 | -27.28 | -175.26% |
The current PE Ratio of Ascendis Pharma A/S (ASND) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-13.73
5-year avg
-16.83
10-year avg
-15.73
Ascendis Pharma A/S’s PE Ratio is greater than Apellis Pharmaceuticals, Inc. (-15.28), greater than BeiGene, Ltd. (-38.25), less than Akero Therapeutics, Inc. (-8.95), greater than Blueprint Medicines Corporation (-26.44), less than Replimune Group, Inc. (-3.26), greater than Nuvalent, Inc. (-32.10), less than Ventyx Biosciences, Inc. (-0.89), less than United Therapeutics Corporation (14.35), greater than IVERIC bio, Inc. (-33.43), less than Amylyx Pharmaceuticals, Inc. (-0.97), greater than Karuna Therapeutics, Inc. (-29.52), less than Day One Biopharmaceuticals, Inc. (-7.39), less than Chinook Therapeutics, Inc. (-11.89), greater than DICE Therapeutics, Inc. (-23.17), less than Pliant Therapeutics, Inc. (-4.19), greater than Crinetics Pharmaceuticals, Inc. (-15.40), less than 89bio, Inc. (-4.84), less than Madrigal Pharmaceuticals, Inc. (-10.23), greater than Arcellx, Inc. (-70.75), less than Stoke Therapeutics, Inc. (-7.92),
Company | PE Ratio | Market cap |
---|---|---|
-15.28 | $5.00B | |
-38.25 | $21.01B | |
-8.95 | $1.83B | |
-26.44 | $5.47B | |
-3.26 | $708.49M | |
-32.10 | $5.59B | |
-0.89 | $153.35M | |
14.35 | $15.38B | |
-33.43 | $5.51B | |
-0.97 | $161.36M | |
-29.52 | $12.60B | |
-7.39 | $1.25B | |
-11.89 | $2.71B | |
-23.17 | $2.27B | |
-4.19 | $782.51M | |
-15.40 | $4.03B | |
-4.84 | $897.06M | |
-10.23 | $5.30B | |
-70.75 | $3.83B | |
-7.92 | $773.92M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ascendis Pharma A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ascendis Pharma A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Ascendis Pharma A/S's PE Ratio?
How is the PE Ratio calculated for Ascendis Pharma A/S (ASND)?
What is the highest PE Ratio for Ascendis Pharma A/S (ASND)?
What is the 3-year average PE Ratio for Ascendis Pharma A/S (ASND)?
What is the 5-year average PE Ratio for Ascendis Pharma A/S (ASND)?
How does the current PE Ratio for Ascendis Pharma A/S (ASND) compare to its historical average?